$RCKT
ROCKET PHARMACEUTICALS, INC.

2020 Q4 Form 10-K Financial Statement

#000114036121006677 Filed on March 01, 2021

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q2 2020
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.200M $6.830M $27.92M
YoY Change 64.66% 55.23% 59.27%
% of Gross Profit
Research & Development $51.04M $16.73M $105.4M
YoY Change 247.92% 19.59% 82.08%
% of Gross Profit
Depreciation & Amortization $630.0K $100.0K $1.100M
YoY Change 530.0% 0.0% 175.0%
% of Gross Profit
Operating Expenses $59.24M $23.56M $134.3M
YoY Change 201.48% 28.09% 76.36%
Operating Profit -$59.24M -$23.56M -$134.3M
YoY Change 201.48% 28.09% 76.36%
Interest Expense -$1.400M -$1.360M $6.967M
YoY Change 211.11% -188.08% 16.94%
% of Operating Profit
Other Income/Expense, Net -$270.0K -$120.0K -$580.0K
YoY Change -208.0% -146.15% -140.56%
Pretax Income -$60.92M -$25.04M -$139.7M
YoY Change 206.75% 34.05% 80.79%
Income Tax
% Of Pretax Income
Net Earnings -$60.92M -$25.04M -$139.7M
YoY Change 206.8% 34.05% 80.79%
Net Earnings / Revenue
Basic Earnings Per Share -$0.45 -$2.52
Diluted Earnings Per Share -$1.082M -$0.45 -$2.52
COMMON SHARES
Basic Shares Outstanding 55.23M 55.16M 55.38M
Diluted Shares Outstanding 55.16M 55.38M

Balance Sheet

Concept 2020 Q4 2020 Q2 2020
SHORT-TERM ASSETS
Cash & Short-Term Investments $482.7M $249.8M $482.7M
YoY Change 58.73% -3.1% 58.73%
Cash & Equivalents $297.1M $163.2M $297.1M
Short-Term Investments $185.6M $86.60M $185.6M
Other Short-Term Assets $4.600M $5.600M $4.600M
YoY Change 27.78% -3.45% 27.78%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $487.3M $255.4M $487.3M
YoY Change 58.36% -3.12% 58.32%
LONG-TERM ASSETS
Property, Plant & Equipment $19.21M $64.80M $70.60M
YoY Change -34.94% 558.27% 123.42%
Goodwill $30.82M
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.000M $2.000M $2.000M
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $103.5M $97.70M $103.5M
YoY Change 60.76% 116.67% 60.96%
TOTAL ASSETS
Total Short-Term Assets $487.3M $255.4M $487.3M
Total Long-Term Assets $103.5M $97.70M $103.5M
Total Assets $590.8M $353.1M $590.8M
YoY Change 58.77% 14.38% 58.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $25.30M $18.70M $25.30M
YoY Change 40.56% 26.35% 40.56%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $6.500M $1.600M $6.500M
YoY Change
Total Short-Term Liabilities $32.62M $20.70M $32.60M
YoY Change 78.15% 37.26% 78.14%
LONG-TERM LIABILITIES
Long-Term Debt $54.10M $65.10M $54.10M
YoY Change 20.22% 50.69% 20.22%
Other Long-Term Liabilities $136.0K $700.0K $600.0K
YoY Change 491.3% 3081.82% -60.0%
Total Long-Term Liabilities $136.0K $65.80M $54.70M
YoY Change 491.3% 298990.91% 17.63%
TOTAL LIABILITIES
Total Short-Term Liabilities $32.62M $20.70M $32.60M
Total Long-Term Liabilities $136.0K $65.80M $54.70M
Total Liabilities $87.31M $86.50M $87.30M
YoY Change 34.68% 43.65% 34.72%
SHAREHOLDERS EQUITY
Retained Earnings -$322.8M
YoY Change 76.28%
Common Stock $610.0K
YoY Change 11.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $503.5M $266.5M $503.5M
YoY Change
Total Liabilities & Shareholders Equity $590.8M $353.1M $590.8M
YoY Change 58.77% 14.38% 58.77%

Cashflow Statement

Concept 2020 Q4 2020 Q2 2020
OPERATING ACTIVITIES
Net Income -$60.92M -$25.04M -$139.7M
YoY Change 206.8% 34.05% 80.79%
Depreciation, Depletion And Amortization $630.0K $100.0K $1.100M
YoY Change 530.0% 0.0% 175.0%
Cash From Operating Activities -$13.11M -$22.03M -$74.64M
YoY Change -33.55% 21.71% 15.43%
INVESTING ACTIVITIES
Capital Expenditures -$14.92M -$4.380M $20.61M
YoY Change 61.3% -33.13% -11.44%
Acquisitions
YoY Change
Other Investing Activities -$39.54M -$1.040M -$67.53M
YoY Change -220.66% -99.14% 329.03%
Cash From Investing Activities -$54.46M -$5.440M -$96.59M
YoY Change -331.55% -95.71% 147.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net -$2.486M
YoY Change 7919.35%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 282.4M 150.0K 283.0M
YoY Change 205.64% -99.82% 59.17%
NET CHANGE
Cash From Operating Activities -13.11M -22.03M -74.64M
Cash From Investing Activities -54.46M -5.440M -96.59M
Cash From Financing Activities 282.4M 150.0K 283.0M
Net Change In Cash 214.9M -27.32M 111.8M
YoY Change 123.36% -54.19% 50.79%
FREE CASH FLOW
Cash From Operating Activities -$13.11M -$22.03M -$74.64M
Capital Expenditures -$14.92M -$4.380M $20.61M
Free Cash Flow $1.810M -$17.65M -$95.25M
YoY Change -117.27% 52.81% 8.32%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001281895
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
9 Cedarbrook Drive
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Cranbury
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Entity File Number
EntityFileNumber
001-36829
CY2020 dei Entity Registrant Name
EntityRegistrantName
Rocket Pharmaceuticals, Inc.
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3475813
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
08512
CY2020 dei City Area Code
CityAreaCode
646
CY2020 dei Local Phone Number
LocalPhoneNumber
440-9100
CY2020 dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
CY2020 dei Trading Symbol
TradingSymbol
RCKT
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2020 dei Entity Small Business
EntitySmallBusiness
false
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 dei Entity Public Float
EntityPublicFloat
734600000
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
61778289
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
297098000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
185383000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
185621000
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
118732000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4626000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3639000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
487345000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
307754000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19206000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
29521000
CY2020Q4 us-gaap Goodwill
Goodwill
30815000
CY2019Q4 us-gaap Goodwill
Goodwill
30815000
CY2020Q4 us-gaap Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
1568000
CY2019Q4 us-gaap Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
1525000
CY2020Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
455000
CY2019Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
455000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
914000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2051000
CY2020Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
50521000
CY2019Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
0
CY2020Q4 us-gaap Assets
Assets
590824000
CY2019Q4 us-gaap Assets
Assets
372121000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
25472000
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
17352000
CY2020Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
4875000
CY2019Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
626000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
957000
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1644000
CY2019Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
0
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
32617000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18309000
CY2020Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
35066000
CY2019Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
45049000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
498000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1443000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54773061
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
60996367
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
18988000
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
0
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
136000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
23000
CY2020Q4 us-gaap Liabilities
Liabilities
87305000
CY2019Q4 us-gaap Liabilities
Liabilities
64824000
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
60996367
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54769030
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
610000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
548000
CY2020Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
0
CY2019Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
4031
CY2020Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
0
CY2019Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
53000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
825794000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
489925000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-42000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
20000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-322843000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-183143000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
503519000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
307297000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
590824000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
372121000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
106382000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
58623000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
53270000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27921000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17528000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17886000
CY2020 us-gaap Operating Expenses
OperatingExpenses
134303000
CY2019 us-gaap Operating Expenses
OperatingExpenses
76151000
CY2018 us-gaap Operating Expenses
OperatingExpenses
71156000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-134303000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-76151000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-71156000
CY2020 rckt Research And Development Incentives
ResearchAndDevelopmentIncentives
0
CY2019 rckt Research And Development Incentives
ResearchAndDevelopmentIncentives
250000
CY2018 rckt Research And Development Incentives
ResearchAndDevelopmentIncentives
186000
CY2020 us-gaap Interest Expense
InterestExpense
6967000
CY2019 us-gaap Interest Expense
InterestExpense
5958000
CY2018 us-gaap Interest Expense
InterestExpense
6039000
CY2020 us-gaap Interest And Other Income
InterestAndOtherIncome
2150000
CY2019 us-gaap Interest And Other Income
InterestAndOtherIncome
3414000
CY2018 us-gaap Interest And Other Income
InterestAndOtherIncome
1690000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-580000
CY2019 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1175000
CY2018 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
801000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-139700000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-77270000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-74518000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.52
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.58
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.89
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55380740
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49010358
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39377666
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-139700000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-77270000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-74518000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-62000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
147000
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-127000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-139762000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-77123000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-74645000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
15519000
CY2018 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0
CY2018 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
86060000
CY2018 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
9300000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
154022000
CY2018 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
148000
CY2018 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
668000
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-127000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13601000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-74518000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
194037000
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
177760000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
31000
CY2019 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
726000
CY2019 rckt Treasury Stock Issued During Period Value Stock Options Exercised
TreasuryStockIssuedDuringPeriodValueStockOptionsExercised
-397000
CY2019 us-gaap Treasury Stock Retired Cost Method Amount
TreasuryStockRetiredCostMethodAmount
0
CY2019 us-gaap Stock Issued During Period Value Treasury Stock Reissued
StockIssuedDuringPeriodValueTreasuryStockReissued
344000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
147000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13371000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-77270000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
307297000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
280763000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2558000
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
7629000
CY2020 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
26562000
CY2020 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
72000
CY2020 us-gaap Stock Issued During Period Value Treasury Stock Reissued
StockIssuedDuringPeriodValueTreasuryStockReissued
591000
CY2020 rckt Treasury Stock Issued During Period Value Stock Options Exercised
TreasuryStockIssuedDuringPeriodValueStockOptionsExercised
-614000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-62000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18567000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-139700000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
503519000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-139700000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-77270000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-74518000
CY2020 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2758000
CY2019 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
3602000
CY2018 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
3059000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1145000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
426000
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
330000
CY2020 rckt Property Plant And Equipment Write Down
PropertyPlantAndEquipmentWriteDown
419000
CY2019 rckt Property Plant And Equipment Write Down
PropertyPlantAndEquipmentWriteDown
0
CY2018 rckt Property Plant And Equipment Write Down
PropertyPlantAndEquipmentWriteDown
0
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
18567000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
13371000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
13601000
CY2020 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
26562000
CY2019 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
0
CY2018 us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
0
CY2020 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2019 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2018 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-317000
CY2020 rckt Accretion Amortization Of Discounts And Premiums Excluding Accretion Income Related To Cash Equivalents Investments
AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments
-580000
CY2019 rckt Accretion Amortization Of Discounts And Premiums Excluding Accretion Income Related To Cash Equivalents Investments
AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments
1066000
CY2018 rckt Accretion Amortization Of Discounts And Premiums Excluding Accretion Income Related To Cash Equivalents Investments
AccretionAmortizationOfDiscountsAndPremiumsExcludingAccretionIncomeRelatedToCashEquivalentsInvestments
801000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1517000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
917000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1505000
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
11015000
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2722000
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
5890000
CY2020 rckt Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-139000
CY2019 rckt Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-87000
CY2018 rckt Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-161000
CY2020 rckt Increase Decrease In Finance Lease Liabilities
IncreaseDecreaseInFinanceLeaseLiabilities
5557000
CY2019 rckt Increase Decrease In Finance Lease Liabilities
IncreaseDecreaseInFinanceLeaseLiabilities
0
CY2018 rckt Increase Decrease In Finance Lease Liabilities
IncreaseDecreaseInFinanceLeaseLiabilities
0
CY2020 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
113000
CY2019 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
0
CY2018 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
0
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-74640000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-64663000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-53788000
CY2020 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0
CY2019 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0
CY2018 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
76348000
CY2020 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
209343000
CY2019 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
184298000
CY2018 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
141087000
CY2020 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
141811000
CY2019 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
168556000
CY2018 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
61276000
CY2020 rckt Payments To Acquire Right Of Use Asset
PaymentsToAcquireRightOfUseAsset
8452000
CY2019 rckt Payments To Acquire Right Of Use Asset
PaymentsToAcquireRightOfUseAsset
0
CY2018 rckt Payments To Acquire Right Of Use Asset
PaymentsToAcquireRightOfUseAsset
0
CY2020 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2019 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2018 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
20000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
20607000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
23269000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1453000
CY2020 rckt Payments Of Security Deposits
PaymentsOfSecurityDeposits
0
CY2019 rckt Payments Of Security Deposits
PaymentsOfSecurityDeposits
0
CY2018 rckt Payments Of Security Deposits
PaymentsOfSecurityDeposits
376000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-96591000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-39011000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5272000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
280763000
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
177760000
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
154022000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2558000
CY2018 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0
CY2020 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
237000
CY2019 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
CY2018 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
282989000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
31000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
148000
CY2020 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
72000
CY2019 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
CY2018 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
CY2020 rckt Payments For Repurchase Of Treasury Stock
PaymentsForRepurchaseOfTreasuryStock
0
CY2019 rckt Payments For Repurchase Of Treasury Stock
PaymentsForRepurchaseOfTreasuryStock
0
CY2018 rckt Payments For Repurchase Of Treasury Stock
PaymentsForRepurchaseOfTreasuryStock
668000
CY2020 us-gaap Proceeds From Sale Of Treasury Stock
ProceedsFromSaleOfTreasuryStock
591000
CY2019 us-gaap Proceeds From Sale Of Treasury Stock
ProceedsFromSaleOfTreasuryStock
344000
CY2018 us-gaap Proceeds From Sale Of Treasury Stock
ProceedsFromSaleOfTreasuryStock
0
CY2020 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
614000
CY2019 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
344000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
177791000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
153502000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
111758000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
74117000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
94442000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
186908000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
112791000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18349000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
298666000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
186908000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
112791000
CY2020 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
1456000
CY2019 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
4424000
CY2018 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
0
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
300000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
226000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
CY2020 rckt Treasury Stock Purchases Paid In Prior Year
TreasuryStockPurchasesPaidInPriorYear
0
CY2019 rckt Treasury Stock Purchases Paid In Prior Year
TreasuryStockPurchasesPaidInPriorYear
726000
CY2018 rckt Treasury Stock Purchases Paid In Prior Year
TreasuryStockPurchasesPaidInPriorYear
0
CY2020 rckt Retirement Of Treasury Stock Noncash
RetirementOfTreasuryStockNoncash
0
CY2019 rckt Retirement Of Treasury Stock Noncash
RetirementOfTreasuryStockNoncash
1393000
CY2018 rckt Retirement Of Treasury Stock Noncash
RetirementOfTreasuryStockNoncash
0
CY2020 rckt Withholding Tax Payable On Shares Withheld In Treasury Stock
WithholdingTaxPayableOnSharesWithheldInTreasuryStock
0
CY2019 rckt Withholding Tax Payable On Shares Withheld In Treasury Stock
WithholdingTaxPayableOnSharesWithheldInTreasuryStock
53000
CY2018 rckt Withholding Tax Payable On Shares Withheld In Treasury Stock
WithholdingTaxPayableOnSharesWithheldInTreasuryStock
0
CY2020 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0
CY2019 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0
CY2018 rckt Reclassification Of Construction In Process To Finance Right Of Use Asset
ReclassificationOfConstructionInProcessToFinanceRightOfUseAsset
0
CY2020 us-gaap Interest Paid Net
InterestPaidNet
2960000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
2990000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
4485000
CY2020 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2018 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
41466000
CY2020 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
7629000
CY2019 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0
CY2018 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0
CY2020 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-62000
CY2019 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
147000
CY2018 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-127000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
20179000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0
CY2018 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0
CY2020 rckt Reclassification Of Construction In Process To Finance Right Of Use Asset
ReclassificationOfConstructionInProcessToFinanceRightOfUseAsset
26465000
CY2019 rckt Reclassification Of Construction In Process To Finance Right Of Use Asset
ReclassificationOfConstructionInProcessToFinanceRightOfUseAsset
0
CY2019 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
26000
CY2018 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2000
CY2020 rckt Number Of Clinical Stage Programs
NumberOfClinicalStagePrograms
4
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-322800000
CY2020Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
482700000
CY2018 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
CY2019 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
CY2020 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
CY2020 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-100000
CY2019 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
100000
CY2018 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-100000
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2018 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2020 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2019 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<div style="display:none;"><br/></div> <div style="text-align: left; text-indent: 27pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Use of Estimates</div> <div><br/></div> <div style="display:none;"><br/></div> <div style="text-align: left; text-indent: 27pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include but are not limited to goodwill impairment, the accrual of research and development expenses, the valuation of equity transactions, and stock-based awards. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.</div>
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
297098000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
185383000
CY2020Q4 us-gaap Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
1568000
CY2019Q4 us-gaap Restricted Cash Equivalents Noncurrent
RestrictedCashEquivalentsNoncurrent
1525000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
298666000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
186908000
CY2020 rckt Grant Funds Offset Against Research And Development Expenses
GrantFundsOffsetAgainstResearchAndDevelopmentExpenses
3600000
CY2019 rckt Grant Funds Offset Against Research And Development Expenses
GrantFundsOffsetAgainstResearchAndDevelopmentExpenses
1200000
CY2018 rckt Grant Funds Offset Against Research And Development Expenses
GrantFundsOffsetAgainstResearchAndDevelopmentExpenses
0
CY2019 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2018 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
0
CY2019 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
300000
CY2018 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
200000
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
21252000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
30426000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2046000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
905000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19206000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
29521000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1100000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
400000
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
300000
CY2020Q4 rckt Research And Development Costs Current
ResearchAndDevelopmentCostsCurrent
14962000
CY2019Q4 rckt Research And Development Costs Current
ResearchAndDevelopmentCostsCurrent
7418000
CY2020Q4 us-gaap Construction Payable Current
ConstructionPayableCurrent
1456000
CY2019Q4 us-gaap Construction Payable Current
ConstructionPayableCurrent
4424000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4875000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2588000
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1122000
CY2019Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1241000
CY2020Q4 us-gaap Regulatory Liability Current
RegulatoryLiabilityCurrent
590000
CY2019Q4 us-gaap Regulatory Liability Current
RegulatoryLiabilityCurrent
562000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1332000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
553000
CY2020Q4 rckt Internal Use Software Current
InternalUseSoftwareCurrent
300000
CY2019Q4 rckt Internal Use Software Current
InternalUseSoftwareCurrent
226000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
835000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
340000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
25472000
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
17352000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020 rckt Common Stock Voting Rights Number Of Votes Per Share
CommonStockVotingRightsNumberOfVotesPerShare
1
CY2019Q1 us-gaap Treasury Stock Shares Retired
TreasuryStockSharesRetired
100000
CY2019Q1 us-gaap Treasury Stock Retired Cost Method Amount
TreasuryStockRetiredCostMethodAmount
1300000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18567000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13371000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13601000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18567000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13371000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13601000
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
30400000
CY2020 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y1M6D
CY2020Q4 rckt Class Of Warrant Or Right Number Of Warrants Exercised
ClassOfWarrantOrRightNumberOfWarrantsExercised
7051
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-139700000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-77270000
CY2018 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-74518000
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55380740
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49010358
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39377666
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.52
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.58
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.89
CY2020 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
610437
CY2019 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
14102
CY2018 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
14102
CY2020 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
11050931
CY2019 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
9608537
CY2018 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
8615997
CY2020 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
13017353
CY2019 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
11243587
CY2018 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
10251047
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.001
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.174
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.158
CY2020 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
0.009
CY2019 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.007
CY2018 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
0.000
CY2020 rckt Effective Income Tax Rate Reconciliation Internal Revenue Code Section382 Limitation Percentage
EffectiveIncomeTaxRateReconciliationInternalRevenueCodeSection382LimitationPercentage
0.000
CY2019 rckt Effective Income Tax Rate Reconciliation Internal Revenue Code Section382 Limitation Percentage
EffectiveIncomeTaxRateReconciliationInternalRevenueCodeSection382LimitationPercentage
0.000
CY2018 rckt Effective Income Tax Rate Reconciliation Internal Revenue Code Section382 Limitation Percentage
EffectiveIncomeTaxRateReconciliationInternalRevenueCodeSection382LimitationPercentage
-0.387
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.350
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.051
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.035
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.135
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.000
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.005
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.021
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.016
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
42613000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
18471000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
643000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1385000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
7406000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3896000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4563000
CY2020Q4 rckt Deferred Tax Assets Debt Discount
DeferredTaxAssetsDebtDiscount
748000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
27825000
CY2020Q4 rckt Deferred Tax Assets Tax Credit Carryforwards Research And Development
DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment
21359000
CY2019Q4 rckt Deferred Tax Assets Tax Credit Carryforwards Research And Development
DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment
2517000
CY2018Q4 rckt Deferred Tax Assets Tax Credit Carryforwards Research And Development
DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment
575000
CY2020Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
23179000
CY2019Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
27652000
CY2018Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
17098000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1189000
CY2019Q4 rckt Deferred Tax Assets Debt Discount
DeferredTaxAssetsDebtDiscount
1460000
CY2018Q4 rckt Deferred Tax Assets Debt Discount
DeferredTaxAssetsDebtDiscount
3652000
CY2020Q4 rckt Deferred Tax Assets Warrants
DeferredTaxAssetsWarrants
5585000
CY2019Q4 rckt Deferred Tax Assets Warrants
DeferredTaxAssetsWarrants
0
CY2018Q4 rckt Deferred Tax Assets Warrants
DeferredTaxAssetsWarrants
0
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
100583000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
51719000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
47794000
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2018Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
48900000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3900000
CY2020Q4 rckt Annual Limitations Under Section382 Of The Internal Revenue Code Amount
AnnualLimitationsUnderSection382OfTheInternalRevenueCodeAmount
1700000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2018Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2019Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
0
CY2020 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1100000
CY2019 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
900000
CY2018 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
800000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
813000
CY2020 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
1711000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
75000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1202000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
78000
CY2020 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
1522000
CY2020 us-gaap Lease Cost
LeaseCost
4046000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
682000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
445000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1124000
CY2020Q4 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
1644000
CY2020Q4 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
1689000
CY2020Q4 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
1736000
CY2020Q4 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
1791000
CY2020Q4 rckt Finance Lease Liability Payments Due After Year Four
FinanceLeaseLiabilityPaymentsDueAfterYearFour
48768000
CY2020Q4 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
55628000
CY2020Q4 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
34996000
CY2020Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
20632000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
914000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
626000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
498000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1124000
CY2020Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
50521000
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1644000
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
18988000
CY2020Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
20632000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
898000
CY2020 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1070000
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y9M18D
CY2020Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P23Y8M12D
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0777
CY2020Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0896
CY2018Q2 rckt Maximum Funding In Strategic Research Collaboration
MaximumFundingInStrategicResearchCollaboration
3500000
CY2018Q2 rckt Funding In Strategic Research Collaboration
FundingInStrategicResearchCollaboration
1400000
CY2018Q2 rckt Funding In Strategic Research Collaboration Upon Execution Of Agreement Remaining Amount
FundingInStrategicResearchCollaborationUponExecutionOfAgreementRemainingAmount
2100000
CY2019Q1 rckt Funding In Strategic Research Collaboration
FundingInStrategicResearchCollaboration
1400000
CY2020 rckt Milestone Payments
MilestonePayments
700000
CY2019Q2 rckt Grant Award For Clinical Development Support
GrantAwardForClinicalDevelopmentSupport
6500000
CY2020Q4 rckt Number Of Grants
NumberOfGrants
2
CY2019 rckt Proceeds From Clinical Development Support
ProceedsFromClinicalDevelopmentSupport
1200000
CY2020Q4 us-gaap Grants Receivable
GrantsReceivable
1100000
CY2020Q4 rckt Grant Award For Clinical Development Support
GrantAwardForClinicalDevelopmentSupport
3700000
CY2020 rckt Term Of Consulting Agreement
TermOfConsultingAgreement
P3Y
CY2020 rckt Termination Notice Period For Business Development Consulting Service Agreement
TerminationNoticePeriodForBusinessDevelopmentConsultingServiceAgreement
P60D
CY2020 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.04
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
300000
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
200000
CY2018 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2020Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
24120000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
23559000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
27387000
CY2020Q4 us-gaap Operating Expenses
OperatingExpenses
59237000
CY2020 us-gaap Operating Expenses
OperatingExpenses
134303000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-24120000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-23559000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-27387000
CY2020Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-59237000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-134303000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-24664000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-25040000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-29080000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-60916000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-139700000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.45
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.45
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.53
CY2020Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.09
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
18945000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
18392000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
19165000
CY2019Q4 us-gaap Operating Expenses
OperatingExpenses
19649000
CY2019Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-19649000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-76151000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-19451000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-18680000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-19284000
CY2019 us-gaap Operating Expenses
OperatingExpenses
76151000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-18945000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-18392000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-19165000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.52
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2019Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-19855000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-77270000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.39
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.58

Files In Submission

Name View Source Status
0001140361-21-006677-index-headers.html Edgar Link pending
0001140361-21-006677-index.html Edgar Link pending
0001140361-21-006677.txt Edgar Link pending
0001140361-21-006677-xbrl.zip Edgar Link pending
brhc10020974_10k.htm Edgar Link pending
brhc10020974_10k_htm.xml Edgar Link completed
brhc10020974_ex10-11.htm Edgar Link pending
brhc10020974_ex10-23.htm Edgar Link pending
brhc10020974_ex21-1.htm Edgar Link pending
brhc10020974_ex23-1.htm Edgar Link pending
brhc10020974_ex31-1.htm Edgar Link pending
brhc10020974_ex31-2.htm Edgar Link pending
brhc10020974_ex32-1.htm Edgar Link pending
brhc10020974_ex4-8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image0.jpg Edgar Link pending
image00003.jpg Edgar Link pending
image00004.jpg Edgar Link pending
image2.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
rckt-20201231.xsd Edgar Link pending
rckt-20201231_cal.xml Edgar Link unprocessable
rckt-20201231_def.xml Edgar Link unprocessable
rckt-20201231_lab.xml Edgar Link unprocessable
rckt-20201231_pre.xml Edgar Link unprocessable
report.css Edgar Link pending
Show.js Edgar Link pending